RXI Pharma (RXII) Reports Q2 Loss of $0.46
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
RXI Pharma (RXII) Announces Research Collaboration with Karolinska Institutet to Develop d-rxRNA Compounds to Improve Functionality & Persistence of T Cells & NK Cells
August 15, 2018 9:27 AM EDTRXi Pharmaceuticals Corporation (NASDAQ: RXII) today announced that it has entered into a research collaboration with the Karolinska Institutet in Stockholm, Sweden. This collaboration will explore RXi's sd-rxRNA compounds against targets involved in T cell and NK cell differentiation and/or in the immune cell tumor-induced stress response with the aim of producing anti-tumor adoptive cell therapy grafts with improved functionality and persistence.
This work will expand on the recently published results from the Kiessling group demonstrating that an sd-rxRNA targeting PD-1 can enhance TIL antitumor activity against melanoma cells in... More
